Breaking News Instant updates and real-time market news.

KDMN

Kadmon

$3.83

0.31 (8.81%)

16:13
09/25/17
09/25
16:13
09/25/17
16:13

Kadmon files to sell common stock and warrants

Kadmon announced its intention to offer and sell shares of its common stock and warrants to purchase shares of its common stock in a public offering pursuant to an existing shelf registration statement. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. Jefferies LLC and Piper Jaffray & Co. are acting as the joint book-running managers for the offering. H.C. Wainwright & Co., LLC is acting as the lead manager for the offering. Kadmon intends to grant the underwriters a 30-day option to purchase additional shares of its common stock and/or additional warrants to purchase shares of its common stock, on the same terms and conditions as the shares and warrants offered in the public offering. Kadmon intends to use the net proceeds from the offering for preclinical and clinical development of its lead product candidates, discovery, research and preclinical studies of its other product candidates and for other general corporate purposes.

  • 25

    Sep

KDMN Kadmon
$3.83

0.31 (8.81%)

08/02/17
PIPR
08/02/17
NO CHANGE
Target $7
PIPR
Overweight
Imbruvica approval in graft versus host positive for Kadmon, says Piper Jaffray
After the FDA expanded the approval of AbbVie (ABBV) and Johnson & Johnson's (JNJ) Imbruvica for the treatment of adults with chronic graft versus host disease, or cGVHD, Piper Jaffray analyst Edward Tenthoff said he views the news as positive for Kadmon's KD025. Imbruvica is tough for patients to tolerate, said Tenthoff, who sees an opportunity for KD025 to more safely treat cGVHD patients. He keeps an Overweight rating and $7 price target on Kadmon shares.
07/11/17
PIPR
07/11/17
NO CHANGE
Target $7
PIPR
Overweight
Kadmon interim Phase II data 'impressive,' says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff views Kadmon's preliminary Phase II data for KD025 in graft versus host disease patients as "impressive." Safety was "clean" and the primary endpoint was met, Tenthoff tells investors in a research note. He reiterates an Overweight rating on the shares with a $7 price target.
03/16/17
WBBS
03/16/17
UPGRADE
WBBS
Hold
Kadmon upgraded to Hold from Sell at WBB Securities
WBB Securities analyst Stephen Brozak upgraded Kadmon to Hold.
03/14/17
PIPR
03/14/17
INITIATION
Target $7
PIPR
Overweight
Kadmon initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff started Kadmon Holdings with an Overweight rating and $7 price target.

TODAY'S FREE FLY STORIES

AJRD

Aerojet Rocketdyne

$34.40

0.51 (1.50%)

05:44
10/23/17
10/23
05:44
10/23/17
05:44
Downgrade
Aerojet Rocketdyne rating change  »

Aerojet Rocketdyne…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

05:30
10/23/17
10/23
05:30
10/23/17
05:30
General news
FX Action: USD-JPY has remained settled under 114.00 »

FX Action: USD-JPY has…

NVS

Novartis

$85.74

-0.42 (-0.49%)

05:29
10/23/17
10/23
05:29
10/23/17
05:29
Hot Stocks
Novartis receives FDA Breakthrough Therapy Designation for Tafinlar/Mekinist »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 06

    Nov

  • 08

    Nov

  • 13

    Nov

  • 30

    Nov

  • 04

    Dec

  • 17

    May

BA

Boeing

$264.75

5.71 (2.20%)

05:25
10/23/17
10/23
05:25
10/23/17
05:25
Hot Stocks
Boeing, Mitsubishi Heavy reach agreement on cost reduction for 787 production »

Boeing and Mitsubishi…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

BAC

Bank of America

$27.17

0.59 (2.22%)

05:24
10/23/17
10/23
05:24
10/23/17
05:24
Hot Stocks
Merrill Lynch fined $45.5M in Britain for not reporting derivative transactions »

Bank of America's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

ATHN

athenahealth

$126.04

9.63 (8.27%)

05:18
10/23/17
10/23
05:18
10/23/17
05:18
Upgrade
athenahealth rating change  »

athenahealth upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TATYY

Tate & Lyle

$33.23

-0.835 (-2.45%)

05:13
10/23/17
10/23
05:13
10/23/17
05:13
Upgrade
Tate & Lyle rating change  »

Tate & Lyle upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIO

Rio Tinto

$48.37

0.24 (0.50%)

05:12
10/23/17
10/23
05:12
10/23/17
05:12
Downgrade
Rio Tinto rating change  »

Rio Tinto downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MELI

MercadoLibre

$235.73

-0.27 (-0.11%)

05:02
10/23/17
10/23
05:02
10/23/17
05:02
Recommendations
MercadoLibre analyst commentary  »

MercadoLibre price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$338.10

-4.32 (-1.26%)

04:59
10/23/17
10/23
04:59
10/23/17
04:59
Initiation
Biogen initiated  »

Biogen assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

CELG

Celgene

$121.33

-14.63 (-10.76%)

04:56
10/23/17
10/23
04:56
10/23/17
04:56
Downgrade
Celgene rating change  »

Celgene assumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 08

    Nov

04:55
10/23/17
10/23
04:55
10/23/17
04:55
General news
Breaking General news story  »

6-Month Bill Auction to…

ASOMY

ASOS

$74.28

1.5 (2.06%)

04:55
10/23/17
10/23
04:55
10/23/17
04:55
Conference/Events
ASOS management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 26

    Oct

04:55
10/23/17
10/23
04:55
10/23/17
04:55
General news
Breaking General news story  »

4-Week Bill Announcement…

04:55
10/23/17
10/23
04:55
10/23/17
04:55
General news
Breaking General news story  »

3-Month Bill Auction to…

PAY

Verifone

$20.06

0.06 (0.30%)

04:55
10/23/17
10/23
04:55
10/23/17
04:55
Conference/Events
Verifone management to meet with Jefferies »

Meeting to be held in Las…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 14

    Dec

PLUG

Plug Power

$2.70

0.17 (6.72%)

04:55
10/23/17
10/23
04:55
10/23/17
04:55
Conference/Events
Plug Power to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 16

    Nov

DDAIF

Daimler AG

$80.57

-1.11 (-1.36%)

04:55
10/23/17
10/23
04:55
10/23/17
04:55
Conference/Events
Daimler AG management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

04:55
10/23/17
10/23
04:55
10/23/17
04:55
General news
Chicago Fed National Activity Index Level to be reported at 08:30 »

September Chicago Fed…

IVC

Invacare

$14.60

0.05 (0.34%)

04:55
10/23/17
10/23
04:55
10/23/17
04:55
Conference/Events
Invacare management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

ALXN

Alexion

$139.02

-1.44 (-1.03%)

04:54
10/23/17
10/23
04:54
10/23/17
04:54
Initiation
Alexion initiated  »

Alexion assumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 26

    Oct

  • 06

    Nov

BIVV

Bioverativ

$60.22

0.49 (0.82%)

04:52
10/23/17
10/23
04:52
10/23/17
04:52
Initiation
Bioverativ initiated  »

Bioverativ assumed with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 06

    Nov

TSRO

Tesaro

$116.40

0.89 (0.77%)

04:50
10/23/17
10/23
04:50
10/23/17
04:50
Downgrade
Tesaro rating change  »

Tesaro assumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 06

    Nov

  • 08

    Nov

AMAG

Amag Pharmaceuticals

$15.60

-0.45 (-2.80%)

04:48
10/23/17
10/23
04:48
10/23/17
04:48
Initiation
Amag Pharmaceuticals initiated  »

Amag Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

  • 02

    Feb

  • 14

    Feb

04:15
10/23/17
10/23
04:15
10/23/17
04:15
General news
FX Action: USD-CAD has remained underpinned »

FX Action: USD-CAD has…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.